Did you find this information helpful?
Eleftha 150mg Injection
Salt Composition : Trastuzumab
Manufacturer : INTAS PHARMACEUTICALS LTD
Origin of Medicine : India
Introduction to Eleftha 150mg Injection
Eleftha 150mg Injection consists of Trastuzumab as an active constituent which is indicated for its use in HER 2 breast cancer. In HER 2 positive patients, the breast cancer cells are mostly composed of HER2 proteins that cause rapid development of cancer tumor by serving as a signal to the cancerous. This medication is also used to treat metastatic gastric cancer with increased levels of HER2 proteins.
Her 2 positive breast cancer are most aggressive in nature. The targeted therapy for her 2 positive breast cancer works by selectively targeting the proteins that are responsible for the growth, development, and spread of cancer. Use effective birth control during the treatment and for at least 7 months after the final dose.
Eleftha 150mg Injection is not recommended for patients aged under 18, patients who have severe breathing problems or need oxygen treatment. It is necessary to let your physician know if you have any heart problems, breathlessness, or have ever had any other cancer treatment. Make sure you inform your physician of all the medicines, including supplements and herbal medicines, you are taking before you start treatment with this medication.
Uses of Eleftha 150mg Injection
Eleftha 150mg Injection is indicated for its use in the following conditions:
- Advanced and metastatic breast cancer
- Metastatic gastric cancer
Therapeutic Effects of Eleftha 150mg Injection
The protein called HER2 (human epidermal growth factor receptor 2) is found in abundant amounts on the surface of certain cancer cells, where it stimulates cancer growth. Eleftha 150mg Injection selectively binds to HER2 and stops the growth of cancer cells.
Interaction of Eleftha 150mg Injection with other drugs
Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional and vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Eleftha 150mg Injection and cause undesirable side effects.
More Information about Eleftha 150mg Injection
- Keep Eleftha 150mg Injection out of sight and reach of children.
- Store between 2˚C and 8˚C.
How to consume Eleftha 150mg Injection
- Eleftha 150mg Injection shall either be administered before or after surgery.
- It will be given as an Intravenous infusion for 90 minutes, if well tolerated it shall be administered within 30 minutes for the next doses.
Safety Advices for Eleftha 150mg Injection
Discuss with your physician before taking this Eleftha 150mg Injection if you are pregnant or think you might be pregnant. Do not take this medicine during the pregnancy unless advised by the doctor to take as it may cause to the unborn baby.
Avoid breastfeeding your baby while on the treatment with Eleftha 150mg Injection atleast for at least seven months after the final dose.
Talk to your doctor if you have any lung conditions before starting treatment with Eleftha 150mg Injection.
You need to tell your physician if you have any liver disorders before starting Eleftha 150mg Injection as it requires dosage adjustment for severe liver impairment.
Consult your doctor to know if it is safe to consume alcohol while you are on treatment with Eleftha 150mg Injection.
Eleftha 150mg Injection can cause unusual tiredness and dizziness. Hence, it is advised to avoid driving or handling machinery during the treatment.
Side Effects of Eleftha 150mg Injection
Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.
- Heart Problems
- Allergic reactions
- Kidney problems
- Breathing difficulties
- Visual disturbances
- Nose bleeds or runny nose
- Hair loss
- Nail disorders
- Weight loss
- Loss of appetite
- Dry mouth
- Liver inflammation
- Muscle pain
- Asthma/ lung disorders
Word of Advice
It is suggested to inform your doctor if you have a history of allergic reactions to Eleftha 150mg Injection to avoid life-threatening complications. If you have a history of lung disorder or breathing problems inform your doctor beforehand before the treatment commencement. Avoid planning for pregnancy and breastfeeding for a minimum of 7 months after the last dose. Monitor your heart parameters regularly during the treatment with Eleftha 150mg Injection as it may impact the functioning of heart.
Q 1. Is Eleftha 150mg Injection used as a monotherapy in treating breast cancer?
Eleftha 150mg Injection is generally given along with the chemotherapy medication such as paclitaxel or docetaxel or platinum compunds. Sometimes, it is also given with hormonal agents for those patients with elevated hormonal status.
Q 2. Does Eleftha 150mg Injection cause heart problems?
Yes, Eleftha 150mg Injection can damage the heart muscles. Hence to prevent the worsening of symptoms, it is advised to do heart check up every 3 months and continue till 2-5 years after the treatment completion.
Q 3. Can I breastfeed while on treatment with Eleftha 150mg Injection?
No, since tends to pass into breast milk, it is unsafe to breastfeed. Hence, It is advised not to breastfeed for a minimum of 7 months after the treatment with Eleftha 150mg Injection.
Q 4. Can Eleftha 150mg Injection be consumed during pregnancy?
No, it is unsafe to consume Eleftha 150mg Injection while you are pregnant or this medicine can cause harm to the baby by reducing the amount of amniotic fluid,the fluid surrounding the womb. It can also cause organ developmental issues such as poor lung development when consumed during pregnancy. If you are planning for pregnancy, it is advised to discuss the birth control methods as this medicine may impair your fertility.
Fact Box of Eleftha 150mg Injection
Molecule name: Trastuzumab
|Therapeutic class: Anti-cancer|
Pharmacological class: HER2 inhibitor
1. Advanced and metastatic breast cancer
2. Metastatic gastric cancer
1. Roche, Electronic Medicines Compendium (EMC), [Revised on Jan 2022] [Accessed on 12th July 2022], https://www.medicines.org.uk/emc/files/pil.3856.pdf
2. Genentech Inc, [Revised on Feb 2021] [Accessed on 12th July 2022], https://www.gene.com/download/pdf/herceptin_prescribing.pdf
3. Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
We maintain strict quality controls on all our partner retailers, so that you always get standard quality products.
100% secure and trusted payment protection
We have a new and dynamic return window policy for medicines and healthcare items. Refer FAQs section for more details.